SCHEMBL20914059

SCHEMBL20914059

COc1cc(N)cc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ HPGD P15428 4/20 0.32
▸ MEN1 O00255 3/20 0.32
▸ KMT2A Q03164 3/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD17B10 Q99714 3/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ APAF1 O14727 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ DCTPP1 Q9H773 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ ADORA2A P29274 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ MAPT P10636 1/20 0.30
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914035 0.91 MAT2A (0.34) MAT2AHTTHPGDMEN1KMT2A
SCHEMBL20914077 0.88 TNKS (0.37) MAT2AHTTHPGDMEN1KMT2A
SCHEMBL20913910 0.88 HPGD (0.33) MAT2AHTTHPGDMEN1KMT2A
SCHEMBL20836952 0.88 MAT2A (0.33) MAT2AHTTHPGDMEN1KMT2A
SCHEMBL20837047 0.87 MAT2A (0.33) MAT2AHTTHPGDMEN1KMT2A
SCHEMBL20914015 0.85 POLB (0.37) MEN1KMT2ANPSR1KDM4EALDH1A1
SCHEMBL20913982 0.85 MAT2A (0.34) MAT2AHTTMEN1KMT2AHSD17B10
SCHEMBL20914141 0.85 HSD17B10 (0.32) MAT2AHTTHPGDMEN1KMT2A
SCHEMBL20914267 0.84 KDM4E (0.38) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL20837038 0.83 ADORA2A (0.34) MAT2AHTTMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 MAT2A 1893/4885HTT 165/4885HPGD 280/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 MAT2A 1893/4885HTT 165/4885HPGD 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback